Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00683319
First received: May 21, 2008
Last updated: September 19, 2013
Last verified: June 2009

May 21, 2008
September 19, 2013
April 2008
March 2034   (final data collection date for primary outcome measure)
  • Overall survival [ Designated as safety issue: No ]
  • Event-free survival [ Designated as safety issue: No ]
  • Response to chemotherapy, if there is residual disease [ Designated as safety issue: No ]
  • Requirement for radiotherapy (i.e., residual disease at the completion of chemotherapy, progressive disease during chemotherapy, or recurrent disease during or after completion chemotherapy) [ Designated as safety issue: No ]
  • Late effects of treatment (i.e., ototoxicity and nephrotoxicity at the completion of chemotherapy and neurocognitive outcomes at 5, 7, 11, and 16 years of age) [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00683319 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday

RATIONALE: Gathering information about how young patients with ependymoma respond to standard combination chemotherapy and learning about the long-term effects of this treatment may help doctors plan better treatment.

PURPOSE: This phase III trial is observing young patients with ependymoma undergoing standard combination chemotherapy.

OBJECTIVES:

Primary

  • To determine the overall survival and event-free survival of all infants diagnosed with ependymoma before their third birthday.
  • To determine the overall survival and event-free survival of infants diagnosed with ependymoma before their third birthday when treated with standard chemotherapy comprising vincristine, carboplatin, high-dose methotrexate, cyclophosphamide, and cisplatin.

Secondary

  • To investigate the reasons why the primary tumor was completely resected in patients who were able to undergo complete resection of the tumor.
  • To continue to investigate the biological characteristics of ependymoma.
  • To correlate functional imaging studies of ependymoma with biological characteristics of the tumor.
  • To provide a standard treatment regimen for patients with residual disease after optimal surgery who have already participated in a phase II study.
  • To prospectively document renal function, hearing, and neurocognitive late effects after completion of study treatment.

OUTLINE: This is a multicenter study. Patients are stratified according to extent of prior surgical resection and presence of metastatic disease (complete resection of tumor vs metastatic disease at diagnosis vs no complete resection of tumor).

Patients receive vincristine IV on days 1, 15, and 29, carboplatin IV over 1 hour on day 1, high-dose methotrexate* IV over 24 hours on day 15, cyclophosphamide IV over 1 hour on day 29, and cisplatin IV over 48 hours on days 43 and 44. Treatment repeats every 8 weeks for 7 courses in the absence of disease progression or unacceptable toxicity. Patients with residual disease after completion of treatment may receive other treatment at the discretion of the investigator.

NOTE: *Patients initially treated on clinical trial CCLG-CNS-2005-03 who have no residual disease do not receive high-dose methotrexate in courses 5-7.

Patients undergo observational assessments comprising physical and neurological examination; MRI/ MRS scanning of the head and spine; and audiology, renal, endocrine, neurocognitive, and quality of life evaluations periodically for at least 5 years after the completion of study treatment.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Brain and Central Nervous System Tumors
  • Cognitive/Functional Effects
  • Long-term Effects Secondary to Cancer Therapy in Children
  • Ototoxicity
  • Drug: carboplatin
  • Drug: cisplatin
  • Drug: cyclophosphamide
  • Drug: methotrexate
  • Drug: vincristine sulfate
  • Procedure: adjuvant therapy
  • Procedure: cognitive assessment
  • Procedure: magnetic resonance imaging
  • Procedure: magnetic resonance spectroscopic imaging
  • Procedure: quality-of-life assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
50
Not Provided
March 2034   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed WHO grade 3 anaplastic (malignant) ependymoma or WHO grade 2 ependymoma, including the following variants:

    • Papillary
    • Cellular
    • Clear cell
    • Tanycytic
  • No myxopapillary ependymoma, subependymoma, or ependymoblastoma
  • Meets 1 of the following criteria:

    • Has undergone complete resection of the primary tumor (prior to starting chemotherapy)

      • Two or more surgical procedures to achieve complete resection allowed
    • Metastatic disease at diagnosis (with or without complete resection of the primary tumor)
    • Unable to undergo complete resection of the primary tumor (with or without metastatic disease)
  • Patients with measurable residual disease (primary or metastatic disease) are eligible provided they undergo treatment on clinical trial CCLG-CNS-2005-03 prior to entering this study
  • Has undergone surgical resection OR completed treatment on clinical trial CCLG-CNS-2005-03 within the past 3 weeks
  • Patients who are unable to tolerate chemotherapy or who do not receive treatment according to the CCLG guidelines for ependymoma due to parental preference or recommendation from the treating physician are eligible

PATIENT CHARACTERISTICS:

  • Able to tolerate IV hydration
  • No active infection

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
up to 2 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00683319
CDR0000590666, CCLG-CNS-2007-09, EU-20835
Not Provided
Not Provided
Children's Cancer and Leukaemia Group
Not Provided
Principal Investigator: Martin W. English, MD Birmingham Children's Hospital
National Cancer Institute (NCI)
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP